Crossmark

Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease

Crossref DOI link: https://doi.org/10.1016/j.parkreldis.2019.03.026

Published Print: 2019-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Hauser, Robert A.

Isaacson, Stuart H.

Ellenbogen, Aaron

Safirstein, Beth E.

Truong, Daniel D. https://orcid.org/0000-0001-6995-8936
Komjathy, Steven F.

Kegler-Ebo, Deena M.

Zhao, Ping

Oh, Charles
Funding

Funding for this research was provided by:

Acorda Therapeutics, Inc

Acorda Therapeutics, Inc

Acorda Therapeutics, Inc
License Information

Text and Data Mining valid from 2019-07-01

Text and Data Mining valid from 2019-07-01

Version of Record valid from 2019-04-01
More Information

This article is maintained by: Elsevier

Article Title: Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease

Journal Title: Parkinsonism & Related Disorders

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.parkreldis.2019.03.026

Content Type: article

Copyright: © 2019 The Authors. Published by Elsevier Ltd.